

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

NCT07492693

Status	RECRUITING
Phase	Phase 2
Sponsor	Changhai Hospital
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (14)

- age ≥18 years;
 - pathologically confirmed gastrointestinal tumors (including esophageal cancer, gastric cancer, colorectal cancer, etc.);
 - during the previous chemotherapy cycle (N-1 cycle), patients had a minimum platelet count of $\geq 75 \times 10^9/L$ and at least one high-risk bleeding factor (a history of bleeding; a previous treatment with platinum agents, gemcitabine, cytarabine, anthracyclines, etc.; b tumor cell bone marrow infiltration; c previous or ongoing radiotherapy, especially to long bones or flat bones such as the pelvis or sternum);
 - during the current chemotherapy cycle (N cycle), patients have a platelet count of $\geq 100 \pm 25 \times 10^9/L$;
 - undergoing treatment cycles of 14 or 21 days and requiring at least one more cycle of therapy.
- ... and 9 more (see full listing online)

Exclusion (11)

- Previous use of TPO-RA drugs;
 - Pre-treatment conditions that cause thrombocytopenia, such as hypersplenism or immune thrombocytopenia;
 - History of thrombosis;
 - Hematologic diseases (anemia, leukemia, autoimmune hemolytic diseases, etc.);
 - Major cardiovascular diseases (acute myocardial infarction, cerebral thrombosis, cerebral hemorrhage, etc.);
- ... and 6 more (see full listing online)

Locations (1 total)

Shanghai Changhai Hospital, Shanghai, China